---
title: Adaptive stimulation improves motor control
nct_id: NCT07216976
phase: NA
status: RECRUITING
sponsor: MedtronicNeuro
study_type: INTERVENTIONAL
canonical_url: "https://parkinsonspathways.com/trial/NCT07216976"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT07216976"
last_fetched: "2026-05-10T14:06:10.545Z"
source: "Parkinson's Pathways (curated)"
---
# Adaptive stimulation improves motor control

**Goal (in five words):** Adaptive stimulation improves motor control

**Official Title:** Adaptive DBS Algorithm for Personalized Therapy in Parkinson's Disease (ADAPT-PD) China Study

**Trial ID:** [NCT07216976](https://clinicaltrials.gov/study/NCT07216976)

## Key Facts

- **Phase:** NA
- **Status:** RECRUITING
- **Study Type:** INTERVENTIONAL
- **Sponsor:** MedtronicNeuro
- **Target Enrollment:** 62 participants
- **Start Date:** 2025-11-19
- **Completion Date:** 2027-01
- **Conditions:** Parkinson's Disease
- **Interventions:** Percept™ PC and Percept RC with Adaptive DBS (aDBS™)
- **Intervention Types:** DEVICE

## Summary For Families

The goal is to make deep brain stimulation more personalized so motor symptoms are better controlled with fewer side effects, by using the brain's own signals to guide when and how much stimulation is delivered. It uses Medtronic's Percept PC with an adaptive DBS algorithm that senses alpha‑beta local field potentials (8 to 30 Hz) from STN or GPi leads and automatically raises or lowers stimulation in real time, working alongside your current Parkinson medications and clinician settings rather than replacing them. Looking for adults 18 and older who already have a Percept PC and compatible bilateral STN or GPi leads, who respond to DBS and have stable medications and stimulation, and who show detectable alpha‑beta signals on screening; people with major depression, incompatible or extra implanted devices, low INS battery life, pregnancy or breastfeeding, or inability to use the patient programmer are excluded.

## Eligibility

- **Minimum age:** 18 Years
- **Sex:** ALL

### Full Criteria

```
Inclusion Criteria:

1. Subjects must meet all general inclusion/exclusion criteria (as assessed at the Enrollment Visit)
2. Subjects must meet the LFP screening inclusion criterion (as assessed at the LFP Screening Visit)

General (Assessed at Enrollment Visit):

1. Subject has idiopathic Parkinson's disease
2. Subject is implanted (\>3 months prior to enrollment for new INS implants or \>1 month from INS replacement) with a Percept PC (Model B35200) or Percept RC (Model B35300) and Medtronic DBS leads (Model 3387, 3389, B33005 or B33015) and extensions (Model 37086 or B34000) bilaterally in the same target (physician confirmed), STN or GPi
3. In the opinion of the investigator, the subject responds to DBS Therapy.
4. Based on the opinion of the investigator, the subject's cDBS parameters and PD medications are stable (no changes within the last 4 weeks) and expected to remain stable from enrollment through the end of the aDBS Evaluation Phase
5. Subject is configured to monopolar or dual monopolar stimulation using contacts 1 and/or 2 (9 and/or 10) on at least one side
6. Subject is willing and able to attend all study-required visits and complete the study procedures (e.g. 1-month recall questionnaires, MDS-UPDRS III, Off stim/Off med visit)
7. Subject (or legally authorized representative) has the ability to understand and provide written informed consent for participation in the study prior to the study-related procedures being conducted
8. Subject is a male or non-pregnant female. If female of child-bearing potential, and if sexually active, must be using, or agree to use, a medically-acceptable method of birth control as confirmed by the investigator

LFP Screening Inclusion Criteria (Conducted during LFP Screening Visit):

1\. Subject has Alpha - Beta band (8-30 Hz) amplitude ≥ 1.2 μVp detected on either left and/or right DBS leads on sensing channels 0-2, 0-3, 1-3, 8-10, 8-11, or 9-11.

Exclusion Criteria:

General (Assessed at the Enrollment Visit):

1. Subject and/or caregiver is unable to utilize the patient programmer
2. Subject has more than one lead in each hemisphere of the brain
3. Subject has cortical leads or additional unapproved hardware implanted in the brain
4. Subject has more than one INS
5. At enrollment, the subject's INS has a predicted battery life of \<1 year
6. Subject has Beck Depression Inventory II (BDI-II)\>25
7. Subject requires diathermy, transcranial magnetic stimulation (TMS), or electroconvulsive therapy (ECT)
8. Subject has a metallic implant in the head, (e.g., aneurysm clip, cochlear implant)
9. Subject has, or plans to obtain, an implanted electrical stimulation medical device anywhere in the body (e.g., cardiac pacemaker, defibrillator, spinal cord stimulator)
10. Subject has, or plans to obtain, an implanted medication pump for the treatment of Parkinson's disease (e.g., DUOPATM infusion pump) and/or portable infusion pump
11. Based on the opinion of the investigator, the subject has an abnormal neurological examination that would preclude them from study participation
12. Subject is breast feeding
13. Subject is under the age of 18 years
14. Subject is currently enrolled in or plans to enroll in any concurrent drug and/or device study that may confound the results of this study as determined by the Medtronic study team
15. Subjects with signal artifact on all 6 aDBS sense pathways (3 each on both DBS leads) which preclude the clinician from setting thresholds
```

## Locations (5)

- Xuanwu Hospital, Beijing, Beijing Municipality, China _(39.9075, 116.3972)_
  - Yuqing Zhang — (CONTACT) — 86108316317 — rs.adapt-pdchinastudy@medtronic.com
  - Yuqing Zhang — (PRINCIPAL_INVESTIGATOR)
- Sun Yat-sen Hospital, Guangzhou, Guangdong, China _(23.1167, 113.2500)_
  - Nu Zhang — (CONTACT) — 020-87331952 — rs.adapt-pdchinastudy@medtronic.com
  - Nu Zhang — (PRINCIPAL_INVESTIGATOR)
- Huashan Hospital, Shanghai, Shanghai Municipality, China _(31.2222, 121.4581)_
  - Jianjun Wu — (CONTACT) — 021-52888041 — rs.adapt-pdchinastudy@medtronic.com
  - Jianjun Wu — (PRINCIPAL_INVESTIGATOR)
- Ruijin Hospital, Shanghai, Shanghai Municipality, China _(31.2222, 121.4581)_
  - Bomin Sun — (CONTACT) — 021-64370045 — rs.adapt-pdchinastudy@medtronic.com
  - Bomin Sun — (PRINCIPAL_INVESTIGATOR)
- West China Hospital, Chengdu, Sichuan, China _(30.6667, 104.0667)_
  - Huifang Shang — (CONTACT) — 028-85423655 — rs.adapt-pdchinastudy@medtronic.com
  - Huifang Shang — (PRINCIPAL_INVESTIGATOR)

## Central Contacts

- Jane Zhang, Principle Clinical Research Specialist — (CONTACT) — +86 18612318110 — jane.zhang7@medtronic.com

---

*Canonical: https://parkinsonspathways.com/trial/NCT07216976*  
*HTML version: https://parkinsonspathways.com/trial/NCT07216976*  
*Source data: https://clinicaltrials.gov/study/NCT07216976*